clinical trial · NCT05496231
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
GlaxoSmithKline·phase2·completed·n = 1,080
Cervical Intraepithelial NeoplasiaHPV9 High formulationHPV9 Medium formulationHPV9 Low formulationGardasil 9
brief summary
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
started
Aug 22, 2022
primary completion
Feb 23, 2024
completion
Feb 25, 2024
last updated
Feb 3, 2025
official title
A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol